Study of Mavacamten Treatment with or without Supervised Exercise for Adults with Hypertrophic Obstructive Cardiomyopathy

What this Trial Is About

This research focuses on patients with hypertrophic obstructive cardiomyopathy HOCM who are classified as New York Heart Association Class I-II and are on stable mavacamten treatment for at least 12 weeks without dosage changes. The study evaluates the safety and effects of adding structured moderate intensity endurance and resistance training compared to usual care, aiming to understand how exercise influences heart function and quality of life in this population. Participants receive either supervised combined endurance and resistance training three times a week for six weeks, or usual care which includes standard physical activity recommendations without supervised training. Group assignment depends on travel time to the training venue patients within one hour travel join the exercise training group, while those traveling longer participate in usual care. All participants are equipped with smart watches and can trigger electrocardiograms if symptoms arise. At the start and after six weeks, participants undergo medical exams, resting and stress echocardiography, and complete quality of life questionnaires. Cardiac biomarkers are assessed, and cardiopulmonary exercise testing measures peak oxygen consumption VO2peak. The primary outcome is safety, monitored by the incidence of ventricular arrhythmias during and shortly after exercise. Secondary outcomes include changes in VO2peak, cardiac biomarkers, echocardiographic variables, quality of life scores, and exercise test parameters.

Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy